{"nctId":"NCT04498832","briefTitle":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","startDateStruct":{"date":"2020-10-21","type":"ACTUAL"},"conditions":["Influenza Immunization","Healthy Volunteers"],"count":2100,"armGroups":[{"label":"Group 1: QIV-HD","type":"EXPERIMENTAL","interventionNames":["Biological: High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)"]},{"label":"Group 2: QIV-SD","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)"]}],"interventions":[{"name":"High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)","otherNames":["QIV-HD"]},{"name":"Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)","otherNames":["QIV-SD"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria :\n\n* Aged greater than or equal to (\\>=) 60 years on the day of inclusion.\n* Able to attend all scheduled visits and complied with all study procedures.\n\nExclusion criteria:\n\n* Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.\n* Receipt of any vaccination with live vaccines within the past 27 days preceding the study vaccination or any vaccination with inactivated vaccines within the past 6 days preceding the study vaccination, or planned receipt of any vaccine prior to Visit 02.\n* Previous vaccination against influenza (in the preceding 6 months) with either the study vaccine or another vaccine.\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months.\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* Known systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the study or to a vaccine containing any of the same substances.\n* Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on Investigator's judgment.\n* Alcohol or substance abuse that, in the opinion of the Investigator might interfere with the study conduct or completion.\n* Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with study conduct or completion.\n* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e.,parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.\n* Personal or family history of Guillain-BarrÃ© syndrome.\n* Neoplastic disease or any hematologic malignancy (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy and participants who have a history of neoplastic disease and have been disease free for \\>=5 years).\n* Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature \\>=37.5 degree Celsius). A prospective participant was not be included in the study until the condition had resolved or the febrile event had subsided.\n* History of convulsions.\n* Any condition that in the opinion of the Investigator could interfere with the evaluation of the vaccine.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":true,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28","description":"GMTs of anti-influenza antibodies were measured using hemagglutination inhibition (HAI) assay for 4 influenza virus strains: A/H1N1, A/H3N2-like, B/Victoria-like, and B/Yamagata. Titers were expressed in terms of 1/dilution.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"309.0","spread":null},{"groupId":"OG001","value":"110.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"540.0","spread":null},{"groupId":"OG001","value":"239.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"354.8","spread":null},{"groupId":"OG001","value":"139.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"795.8","spread":null},{"groupId":"OG001","value":"254.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority Analysis","description":"Anti-influenza antibodies were measured by HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2-like, B/Victoria-like, and B/Yamagata. Seroconversion was defined as either a pre-vaccination HAI titer less than (\\<) 10 (1/dilution) and a post-vaccination titer \\>=40 (1/dilution) or a pre-vaccination titer \\>=10 (1/dilution) and a \\>= four-fold increase in post-vaccination titer at Day 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null},{"groupId":"OG001","value":"47.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":null},{"groupId":"OG001","value":"47.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.2","spread":null},{"groupId":"OG001","value":"47.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":null},{"groupId":"OG001","value":"39.0","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs of Influenza Vaccine Antibodies at Day 0 and Day 28","description":"GMTs of anti-influenza antibodies were measured using HAI assay for 6 influenza virus strains: A/H1N1, A/H3N2, A/H3N2-like, B/Victoria, B/Victoria-like, and B/Yamagata. Titers were expressed in terms of 1/dilution.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"309.0","spread":null},{"groupId":"OG001","value":"110.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.9","spread":null},{"groupId":"OG001","value":"54.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"721.4","spread":null},{"groupId":"OG001","value":"319.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.8","spread":null},{"groupId":"OG001","value":"41.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"540.0","spread":null},{"groupId":"OG001","value":"239.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"24.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"447.3","spread":null},{"groupId":"OG001","value":"152.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null},{"groupId":"OG001","value":"22.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"354.8","spread":null},{"groupId":"OG001","value":"139.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.4","spread":null},{"groupId":"OG001","value":"60.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"795.8","spread":null},{"groupId":"OG001","value":"254.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers Ratio (GMTR) of Influenza Vaccine Antibodies","description":"GMTs of anti-influenza antibodies were measured using HAI assay for 6 influenza virus strains: A/H1N1, A/H3N2, A/H3N2-like, B/Victoria, B/Victoria-like, and B/Yamagata. GMTRs were calculated as the ratio of GMTs post-vaccination (on Day 28) and pre-vaccination (on Day 0).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.33","spread":null},{"groupId":"OG001","value":"7.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.14","spread":null},{"groupId":"OG001","value":"5.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.23","spread":null},{"groupId":"OG001","value":"5.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.06","spread":null},{"groupId":"OG001","value":"6.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.97","spread":null},{"groupId":"OG001","value":"6.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.29","spread":null},{"groupId":"OG001","value":"4.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens","description":"Anti-influenza antibodies were measured by HAI assay for 6 influenza virus strains: A/H1N1, A/H3N2, A/H3N2-like, B/Victoria, B/Victoria-like, and B/Yamagata. Seroconversion was defined as either a pre-vaccination HAI titer \\<10 (1/dilution) and a post-vaccination titer \\>=40 (1/dilution) or a pre-vaccination titer \\>=10 (1/dilution) and a \\>= four-fold increase in post-vaccination titer at Day 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null},{"groupId":"OG001","value":"47.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.4","spread":null},{"groupId":"OG001","value":"48.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":null},{"groupId":"OG001","value":"47.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":null},{"groupId":"OG001","value":"47.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.2","spread":null},{"groupId":"OG001","value":"47.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":null},{"groupId":"OG001","value":"39.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HAI Titers >=40 (1/Dilution) Against Influenza Antigens","description":"Anti-influenza antibodies were measured using HAI assay method for 6 influenza virus strains: A/H1N1, A/H3N2, A/H3N2-like, B/Victoria, B/Victoria-like, and B/Yamagata. Percentage of participants with HAI titers \\>=40 (1/dilution) is reported in the outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null},{"groupId":"OG001","value":"67.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":null},{"groupId":"OG001","value":"51.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"93.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null},{"groupId":"OG001","value":"43.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"88.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":null},{"groupId":"OG001","value":"27.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null},{"groupId":"OG001","value":"81.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.1","spread":null},{"groupId":"OG001","value":"24.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"79.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":null},{"groupId":"OG001","value":"56.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"92.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs)","description":"An AE was any untoward medical occurrence in a patient or in a clinical investigation participant administered a medicinal product and which did not necessarily have a casual relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. All participants were observed for 30 minutes after vaccination, and any unsolicited AEs that occurred during that time were recorded as immediate unsolicited AEs in the CRB.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Solicited Injection Site and Systemic Reactions","description":"A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the product administered. Solicited injection site reactions included injection site pain, injection site erythema, injection site swelling, injection site induration, and injection site bruising. Solicited systemic reactions included fever, headache, malaise, myalgia and shivering.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"503","spread":null},{"groupId":"OG001","value":"334","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"328","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"185","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"197","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Unsolicited Adverse Events (AEs)","description":"An AE was any untoward medical occurrence in a patient or in a clinical investigation participant administered a medicinal product and which did not necessarily have a casual relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Serious Adverse Events (SAEs)","description":"A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":1049},"commonTop":["Injection Site Pain","Injection Site Erythema","Myalgia","Injection Site Swelling","Headache"]}}}